[go: up one dir, main page]

IL149924A0 - Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases - Google Patents

Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases

Info

Publication number
IL149924A0
IL149924A0 IL14992400A IL14992400A IL149924A0 IL 149924 A0 IL149924 A0 IL 149924A0 IL 14992400 A IL14992400 A IL 14992400A IL 14992400 A IL14992400 A IL 14992400A IL 149924 A0 IL149924 A0 IL 149924A0
Authority
IL
Israel
Prior art keywords
alzheimer
vaccine
prevention
treatment
related diseases
Prior art date
Application number
IL14992400A
Original Assignee
Neurochem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurochem Inc filed Critical Neurochem Inc
Publication of IL149924A0 publication Critical patent/IL149924A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
IL14992400A 1999-11-29 2000-11-29 Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases IL149924A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16859499P 1999-11-29 1999-11-29
US72484200A 2000-11-28 2000-11-28
PCT/CA2000/001413 WO2001039796A2 (en) 1999-11-29 2000-11-29 Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases

Publications (1)

Publication Number Publication Date
IL149924A0 true IL149924A0 (en) 2002-11-10

Family

ID=26864284

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14992400A IL149924A0 (en) 1999-11-29 2000-11-29 Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases

Country Status (13)

Country Link
EP (1) EP1235587A2 (en)
JP (1) JP2004500354A (en)
KR (2) KR20080059676A (en)
CN (1) CN1433321A (en)
AU (1) AU784312B2 (en)
BR (1) BR0016022A (en)
CA (1) CA2388559A1 (en)
HK (1) HK1049279A1 (en)
IL (1) IL149924A0 (en)
MX (1) MXPA02005576A (en)
NO (1) NO20022531L (en)
NZ (1) NZ540564A (en)
WO (1) WO2001039796A2 (en)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997021728A1 (en) 1995-12-12 1997-06-19 Karolinska Innovations Ab PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b)
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US20020094335A1 (en) * 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
KR100879810B1 (en) * 2000-02-21 2009-01-22 하. 룬드벡 아크티에셀스카브 Novel method for down-regulation of amyloid
EP2082749A3 (en) 2000-07-07 2010-06-30 Bioarctic Neuroscience AB Prevention and treatment of Alzheimer's disease
AU2007200047B2 (en) * 2000-07-07 2009-11-26 Bioarctic Neuroscience Ab Prevention and treatment of Alzheimer's disease
US7311893B2 (en) 2000-07-25 2007-12-25 Neurochem (International) Limited Amyloid targeting imaging agents and uses thereof
US20020115717A1 (en) * 2000-07-25 2002-08-22 Francine Gervais Amyloid targeting imaging agents and uses thereof
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
MY144532A (en) 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
AR038568A1 (en) * 2002-02-20 2005-01-19 Hoffmann La Roche ANTI-A BETA ANTIBODIES AND ITS USE
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
JP2006511452A (en) 2002-07-03 2006-04-06 バイオ サイエンス インターナショナル インコーポレイテッド Peptide containing aromatic D-amino acid and method of using the same
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid β (1-42) oligomers, process for their preparation and their use
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
TWI374893B (en) 2003-05-30 2012-10-21 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
WO2004113275A2 (en) * 2003-06-23 2004-12-29 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
BRPI0417689A8 (en) * 2003-12-17 2017-04-25 Elan Pharm Inc METHOD FOR CONJUGATING A PEPTIDE IMMOGEN, COMPOSITION, CONJUGATE, IMMUNOGENIC COMPOSITION, METHOD FOR INDUCING AN IMMUNE RESPONSE IN A MAMMAL INDIVIDUAL, AND, USE OF THE CONJUGATE
SE0401601D0 (en) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
WO2006066089A1 (en) 2004-12-15 2006-06-22 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
CN101128421A (en) 2004-12-22 2008-02-20 神经化学（国际）有限公司 Methods and compositions for treating amyloid-related diseases
KR100851035B1 (en) 2005-08-23 2008-08-11 대한민국 - - Pharmaceutical composition and composition for screening therapeutics to preventing and treating of -amyloid accumulation in brain comprising GCP-Glutamate carboxypeptidase- as an active ingredient method for screening using said composition
EP1951750A4 (en) 2005-11-10 2009-12-09 Roskamp Res Llc Modulation of angiogenesis by a-beta peptide fragments
EP1954718B1 (en) 2005-11-30 2014-09-03 AbbVie Inc. Anti-a globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
SG10201706600VA (en) 2005-11-30 2017-09-28 Abbvie Inc Monoclonal antibodies and uses thereof
ATE517923T1 (en) 2005-12-12 2011-08-15 Hoffmann La Roche ANTIBODIES AGAINST AMYLOID BETA WITH GLYCOSYLATION IN THE VARIABLE REGION
NO346055B1 (en) * 2005-12-12 2022-01-24 Ac Immune Sa Antigen design, vaccine composition and method of manufacture thereof.
AU2007227813B2 (en) 2006-03-23 2012-09-27 Bioarctic Neuroscience Ab Improved protofibril selective antibodies and the use thereof
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
MX2009000476A (en) 2006-07-14 2009-01-28 Ac Immune Sa Humanized antibody against amyloid beta.
KR20190003862A (en) * 2006-07-14 2019-01-09 에이씨 이뮨 에스.에이. Humanized antibody against amyloid beta
BRPI0719763A2 (en) * 2006-10-02 2014-01-28 Ac Immune Sa ANTIBODY, NUCLEIC ACID MOLECULE, EXPRESSION VECTOR, CELL, COMPOSITION, MIXTURE, USE OF A CHEMICAL ANTIBODY OR A FRAGMENT OF THE SAME OR A FRAGMENT OF THE SAME AND / OR A PART OR A FUNCTION OR A PART OR A FUNCTION MIXTURE, METHODS FOR PREPARING A PHARMACEUTICAL COMPOSITION OR MIXTURE, TO PREVENT, TREAT OR RELIEVE THE EFFECTS OF A DISEASE, DIAGNOSTIC DISEASE, OR CONDITION ASSOCIATED WITH A DETERMINATION OF THE DETERMINATION OF CAROGUE DETERMINATION IN A FABRIC AND / OR BODY FLUIDS, TEST KITS FOR DISEASE AND DIAGNOSTIC TESTING AND CONDITIONS ASSOCIATED WITH AMYLOID, LIGHT CHAIN VARIABLE REGION, HEAVY CIRCLE, GENELE DESENGER, GENELE DIAGET LINES PRE-FORMED BETA-AMYLOID FIBERS TO PREVENT ABETA-INDUCED NEURON DEGRADATION, TO DIAGNOSE A PREDISPOSITION TO A DISEASE OR CO NDITION ASSOCIATED WITH AMYLOID IN A PATIENT, TO MONITOR MINIMUM RESIDUAL DISEASE IN A PATIENT, TO PROGNOSE LIABILITY OF A PATIENT WHO IS TREATED WITH AN ANTIBODY OR A COMPOSITION OF VACCINE, TO REDUCE THE CARBON LOAD TO THE CIRCLE THE NUMBER OF PLATES IN AN ANIMAL BRAIN, TO REDUCE THE TOTAL SOLUBLE OPEN QUANTITY IN AN ANIMAL BRAIN AND TO HOLD OR INCREASE COGNITIVE MEMORY CAPACITY IN A MAMMALIAN.
PL3851447T3 (en) 2006-10-12 2024-03-04 Bellus Health Inc. Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
TR201802286T4 (en) 2007-04-20 2018-03-21 The Chemo Sero Therapeutic Res Institute Method for enhancing the immune response with the peptide.
JP2010528583A (en) * 2007-06-11 2010-08-26 エーシー イミューン ソシエテ アノニム Humanized antibody against amyloid β
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
DK2182983T3 (en) 2007-07-27 2014-07-14 Janssen Alzheimer Immunotherap TREATMENT OF AMYLOIDOGENIC DISEASES WITH HUMANIZED ANTI-ABETA ANTIBODIES
RU2604181C2 (en) 2007-10-05 2016-12-10 Дженентек, Инк. Using anti-amyloid beta antibody in ophthalmic diseases
JO3076B1 (en) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap Immunotherapy regimes dependent on apoe status
WO2009143489A2 (en) * 2008-05-22 2009-11-26 Archer Pharmaceuticals, Inc. Modulation of angiogenesis by a-beta peptide fragments
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
EP2273273A1 (en) * 2009-07-11 2011-01-12 Rheinische Friedrich-Wilhelms-Universität Bonn Inhibitors of the nitration of amyloid ß peptides and their uses in the diagnosis and treatment of alzheimer's disease
JP2013523182A (en) 2010-04-15 2013-06-17 アボット・ラボラトリーズ Amyloid beta-binding protein
US9221900B2 (en) 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies
EP2603524A1 (en) 2010-08-14 2013-06-19 AbbVie Inc. Amyloid-beta binding proteins
CN106661103B (en) 2014-07-10 2020-11-03 生命北极神经科学公司 Improved Aβ protofibril-binding antibody
BR112017024610A2 (en) 2015-06-24 2018-07-31 F. Hoffmann-La Roche Ag specific affinity antitransferrin receptor antibodies
AR106189A1 (en) 2015-10-02 2017-12-20 Hoffmann La Roche BIESPECTIFIC ANTIBODIES AGAINST HUMAN A-b AND THE HUMAN TRANSFERRINE RECEIVER AND METHODS OF USE
NZ741067A (en) 2015-10-02 2023-07-28 Hoffmann La Roche Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
WO2017079835A1 (en) 2015-11-09 2017-05-18 The University Of British Columbia Amyloid beta epitopes and antibodies thereto
KR20180085736A (en) 2015-11-09 2018-07-27 더 유니버시티 오브 브리티쉬 콜롬비아 Amyloid beta mid-region epitopes and structurally selective antibodies thereto
KR102550991B1 (en) 2016-07-18 2023-07-04 더 유니버시티 오브 브리티쉬 콜롬비아 Antibodies to amyloid beta
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008868A1 (en) * 1996-08-27 1998-03-05 Praecis Pharmaceuticals Incorporated MODULATORS OF β-AMYLOID PEPTIDE AGGREGATION COMPRISING D-AMINO ACIDS
NO314086B1 (en) * 1998-05-08 2003-01-27 Gemvax As Peptides and pharmaceutical compositions containing them, nucleic acid sequences encoding such peptides, plasmids and virus vectors encompassing such DNA sequences and their use for the preparation of pharmaceutical preparations for
CA2388092A1 (en) * 1999-05-05 2000-11-16 Neurochem, Inc. Stereoselective antifibrillogenic peptides and peptidomimetics thereof

Also Published As

Publication number Publication date
AU784312B2 (en) 2006-03-09
MXPA02005576A (en) 2002-12-13
CA2388559A1 (en) 2001-06-07
KR20080059676A (en) 2008-06-30
CN1433321A (en) 2003-07-30
KR20020073341A (en) 2002-09-23
NO20022531D0 (en) 2002-05-28
HK1049279A1 (en) 2003-05-09
NO20022531L (en) 2002-07-12
EP1235587A2 (en) 2002-09-04
NZ540564A (en) 2007-04-27
BR0016022A (en) 2002-08-06
AU1847301A (en) 2001-06-12
JP2004500354A (en) 2004-01-08
WO2001039796A3 (en) 2001-12-06
WO2001039796A2 (en) 2001-06-07

Similar Documents

Publication Publication Date Title
IL149924A0 (en) Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
HUP0103654A2 (en) Use of smilagenin and anzurogenin-d for production of pharmaceutical compositions for the treatment of alzheimer's disease
SI1303272T1 (en) Benzothiazole derivatives for the treatment of alzheimer's disease and parkinson's disease
AU2001249835A1 (en) Diagnosis and treatment of alzheimer's disease
GB2368794B (en) Prevention and treatment of amyloidogenic disease
HUP0201205A2 (en) Prevention and treatment of amyloidogenic disease
HUP0003852A3 (en) Use of highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias
AU2002335794A1 (en) Allylamides useful in the treatment of alzheimer's disease
NO20001869D0 (en) Procedures for the treatment of Alzheimer's disease
AU2002212471A1 (en) Peptides for use in the treatment of alzheimer's disease
AU3840802A (en) Methods and compositions for the treatment of diseases of the eye
GB0004531D0 (en) The treatment of respiratory diseases
HUP0104963A3 (en) Compositions for the treatment of skin diseases
AU2002222108A1 (en) Diagnosis and treatment of alzheimer's disease
IL117695A0 (en) Pharmaceutical agents for the treatment of alzheimer's disease
GB0011410D0 (en) Therapeutic combination for treating Alzheimer's disease
AU5550800A (en) Diagnosis and treatment of alzheimer's disease
AU2003248660A8 (en) Treatment of vascular dysfunction and alzheimer's disease
GB0011430D0 (en) Acombination of therapeutic agents for treating Alzheimer's Disease
EP1181550A4 (en) Methods for the identification of compounds for the treatment of alzheimer's disease
PL377110A1 (en) Prevention and treatment of alzheimer's disease
IL153439A0 (en) Medicines for the prevention and treatment of neurodegenerative diseases
AU2001262741A1 (en) Medicines for the prevention and treatment of neurodegenerative diseases
HUP0103149A3 (en) Pharmaceutical composition for treatment of alzheimer's disease
AU2002319451A1 (en) Therapeutic strategies for prevention and treatment of alzheimer's disease